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Recombinant thrombomodulin monotherapy for secondary thrombotic
thrombocytopenic purpura☆,☆☆Abstract
The use of plasma exchange for the treatment of thrombotic throm-
bocytopenic purpura (TTP) has reduced the mortality rate, but it
remains high, at 20%. Steroids, rituximab, and eculizumab are some-
times used in addition to plasma exchange, but their use is associated
with adverse effects, including immunosuppression. Several studies re-
ported that the concomitant use of recombinant thrombomodulin
(rTM) in the treatment of TTP was useful; however, no studies have re-
ported the successful treatment of TTP with rTM alone. We present the
ﬁrst case of TTP successfully treated by rTM. Because previous studies
showed that rTM alleviates vascular endothelial damage, this agent is
also theoretically useful for the treatment of TTP. Recombinant
thrombomodulin would be signiﬁcant in alleviating vascular endotheli-
al damage and decreasing the organ's damage.
Thrombotic thrombocytopenic purpura (TTP) is associated with de-
creased activity of ADAMTS-13, an enzyme that cleaves ultra-large von
Willebrand multimers (UL-VWFM). In autoimmune TTP, a decrease in
ADAMTS-13 activity due to anti-ADAMTS autoantibodies results in the
excessive aggregation of platelets with uncleaved UL-FWFM, leading
to vascular endothelial ischemic damage [1]. Thrombotic thrombocyto-
penic purpura is treated by plasma exchange and fresh-frozen plasma
administration; however, TTP often resists treatment, and even after
successful treatments, organ dysfunction may persist.
Meanwhile, it has been indicated that in ADAMTS-13 inhibitor–
negative patients, the excessive release ofUL-VWFMdue to inﬂammation
or other causes may contribute to the development of secondary TTP [2].
In this case, ADAMTS-13 activity is not signiﬁcantly decreased [3].
Therapeutic options for TTP other than plasma exchange and
fresh-frozen plasma infusion are steroids [4], rituximab [5], and
eculizumab [6]. However, they are often associated with adverse ef-
fects such as immunosuppression.
Recombinant thrombomodulin (rTM), a drug product developed
in Japan and composed of the bioactive domains of thrombomodulin,
has the effect of reducing vascular endothelial damage. It is theoret-
ically effective for the treatment of TTP. Herein, we report a
patient with secondary TTP who was successfully treated by
rTM monotherapy.
A 76-year-old woman vomited, became incontinent, and was found
unconscious at home. Shewas rushed by ambulance to our hospital. She☆ Name of organization and date of assembly: Hitachi General Hospital.
☆☆ Source(s) of support in the form of equipment, drugs, or grants (including grant
numbers): None.
0735-6757/© 2014 The Authors. Published by Elsevier Inc. This is an open access article underhad no medical history of note and was not taking any medication. Her
temperature was 33.9°C; blood pressure, 89/56 mm Hg; heart rate, 83
beats/min; SpO2, 100% (room air); and Glasgow Coma Scale score,
E4V3M6. The laboratory data are shown in Table 1.
For macrocytic anemia, the transfusion of red blood cells and
administration of vitamin B12 and folic acid were started. After ad-
mission, the platelet count fell to 14000/μL, and so 20 U of platelets
was transfused. Because blood tests on the ﬁfth hospital day revealed
thrombocytopenia (platelet count, 53000/μL) and coagulation ab-
normalities (ﬁbrin degradation products [FDP] 23 μg/dL, prothrom-
bin time 72%), the administration of 12800 units of rTM was
started to alleviate vascular endothelial damage.
The peripheral blood smear showed fragmented red blood cells, sug-
gesting TTP, so additional tests were ordered, the results of which are
also shown in Table 1.
These ﬁndings led to a diagnosis of TTP, which improvedmarked-
ly after rTM administration. The patient's prognosis at the start of
rTM therapy was not poor, with a Rose index of TTP severity of 3,
and so no plasma exchange or fresh-frozen plasma replacement
was performed.
Figure shows the time course of changes in platelet counts and FDP
levels. Because the platelet count was restored, rTM was discontinued
on the ninth hospital day. On the 11th hospital day, the platelet count
and FDP level had returned to the reference range, and the ADAMTS-
13 and vonWillebrand factor activity levels were 48% and 206%, respec-
tively. Because her general condition and blood examination data im-
proved, she was discharged, walking unaided.
Thrombomoduin is known to protect vascular endothelium by
activating protein C and degrading inﬂammatory materials [7–9],
and circulating thrombomodulin levels are markedly elevated in pa-
tients with TTP. However, these circulating thrombomodulin has
very low bioactivity, and the activity of vascular endothelial
thrombomodulin is decreased [10]. So we consider that replacement
therapy with rTM products compensates for the decreased activity
of thrombomodulin.
Secondary TTP occurs as a result of increased production and release
of UL-VWFM by inﬂammatory cytokines [11]. Secondary TTP is less re-
sponsive to plasma exchange [12], presumably because plasma ex-
change can remove ADAMTS-13 inhibitors, but cannot suppress the
vascular endothelial injury–induced production of UL-VWFM. So in
this condition, immediate improvement of vascular endothelial damage
seems important.
As far as we searched, 9 cases TTP were treated with rTM [13–17].
These cases are summarized in Table 2. Of note, none of them, except
for our case, were treated with rTM alone. All patients had secondary
TTP, and the treatment with rTM restored their platelet counts and
reversed their decreased FDP levels, alleviating vascular endothelialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Laboratory test
White blood cell count 7200/μL Antinuclear antibody Negative
Hemoglobin 4.7 g/dL Blood culture Negative
Mean corpuscular volume 128 fL
Platelet count 81000/μL
Prothrombin time 13.3 s
Activated partial thrombin time 31.2 s
Fibrinogen 241 mg/dL
FDPs 3.3 μg/mL
D-dimer 1 μg/mL
Antithrombin III 51%
Total protein 6.6 g/dL
Albumin 4.1 g/dL
Direct bilirubin 4.8 mg/dL Additional test
Indirect bilirubin 2.3 mg/dL Von-Willebrand factor activity 375% Reference range, 60%-170%
Blood urea nitrogen 48.4 mg/dL
Creatinin 1.4 mg/dL ADAMTS-13 activity 45% Reference range, 70%-120%
Lactate dehydrogenase 1965 U/L ADAMTS-13 inhibitor Negative
Haptoglobin 2 mg/dL Thrombomodulin N32 FU/mL Reference range, 1.8-3.9 FU/mL
Vitamin B12 50 pg/mL
Folic acid 9.4 pg/mL
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and vascular endothelial damage in the context of hypothermia resulted
in an increased release of UL-VWFM, leading to the development of TTP.
In patients with ADAMTS-13 inhibitor–positive primary TTP, plasma
exchange should be indicated to replenish ADAMTS-13 and remove the
inhibitors. However, rTM would be also signiﬁcant to alleviate vascular
endothelial damage and decrease the organ's damage.
The administration of rTMmay improve TTP condition, especially in
secondary TTP. It would shorten the treatment duration and reduce the
organ damage.
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Table 2
Cases rTM is used for TTP
Nishijima et al [13] Okada et al [14] Tonooka
et al [15]
Sakai et al [16] Inoue et al [17] Our present case
Age (y) 61 1 33 24 n/a 76
Sex Female Female Female Female n/a Female
Underlying condition Gemcitabine + bevacizumab for small
cell lung cancer
Umbilical
cord
blood;
transplan-
tation for
familial
hemopha-
gocytic
lymphohistiocytosis TMA associated with SLE Peripheral blood
stem cell
transplantation
for DLBCL
Refractory
TMA as-
sociated
with
acute
GVHD af-
ter intes-
tinal
transplantation Hypothermia and vitamin B12
deﬁciency
ADAMTS-
13
activity
61% n/a 69.8% N60% n/a 45%
ADAMTS-
13
inhibitor
Negative n/a Negative n/a n/a Negative
Treatments FFP + rTM PSL + MMF + rTM PSL + CPA
+ rTM
Rituximab + rTM PSL + CPA + rTM rTM
Outcome Cured Cured Cured Cured Cured Cured
n/a indicates not available; FFP, fresh-frozen plasma; PSL, predonisolone; MMF, mycophenolate mofetil; CPA, cyclophosphamide; CyA, cyclosporin.
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